Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
PLAINSBORO, N.J., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (“Integra”) (NASDAQ:IART), a global leader in medical technology, announced today that its tender...
PLAINSBORO, N.J., Jan. 25, 2017 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (“Integra”) (NASDAQ:IART), a global leader in medical technology, announced today that its...
Harwood Feffer LLP Announces Investigation of Derma Sciences Inc. PR Newswire NEW YORK, Jan. 17, 2017 NEW YORK, Jan. 17, 2017 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating...
Secures 10-year Supply Source Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, today announced that it has purchased the...
Rigrodsky & Long, P.A.: Do you own shares of Derma Sciences, Inc. (NASDAQ CM: DSCI)? Did you purchase any of your shares prior to January 11, 2017? Do you think the proposed...
DERMA (DSCI) ALERT: Johnson & Weaver, LLP Launches an Investigation into the Fairness of Price and Process in Proposed Sale of Derma Sciences, Inc.; Is $7 a Fair Price? PR Newswire SAN DIEGO...
Expands regenerative technology capabilities and accelerates advanced wound care strategy with the addition of amniotic tissue-based productsLeverages existing sales channel with the addition...
-- Appoints Four New, Highly Qualified Independent Directors: Jason Aryeh, Dr. Geoffrey Cox, Robert Forrester and Bob Oliver --– -- Announces Chairman and CEO Succession Plans --– -- Mails...
Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, announced today that Stephen T. Wills, the Company’s Executive Chairman and...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Premium
